CR11244A - DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME - Google Patents
DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAMEInfo
- Publication number
- CR11244A CR11244A CR11244A CR11244A CR11244A CR 11244 A CR11244 A CR 11244A CR 11244 A CR11244 A CR 11244A CR 11244 A CR11244 A CR 11244A CR 11244 A CR11244 A CR 11244A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compositions
- methods
- mek
- compounds
- arilamino
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 abstract 1
- 238000007707 calorimetry Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Esta invencion se relaciona con compuestos N-(2-arilamino) aril sulfonamida que son inhibidores de MEK incluyendo formas polimorficas cristalinas que exhiben un perfil de difraccion de rayos X en polvo especifiico y/o un perfil de calorimetria diferencial de barrido especifico. Esta invencion tambien se relaciona con composiones farmaceuticas que comprenden los compuestos descritos y metodos de uso de los compuestos y composiciones descritos, incluyendo el uso en el tratamiento y/o prevencion de cancer, enfermedades hiperproliferativas y condiciones inflamatorias. La invencion tambien se relaciona con metodos para obtener los compuestos y composiciones que se describen.This invention relates to N- (2-arylamino) aryl sulfonamide compounds that are MEK inhibitors including crystalline polymorphic forms that exhibit a specific powder X-ray diffraction profile and / or a specific scanning differential calorimetry profile. This invention also relates to pharmaceutical compositions comprising the described compounds and methods of use of the described compounds and compositions, including use in the treatment and / or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also relates to methods for obtaining the compounds and compositions described.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/830,733 US8101799B2 (en) | 2005-07-21 | 2007-07-30 | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| US3446408P | 2008-03-06 | 2008-03-06 | |
| US3446608P | 2008-03-06 | 2008-03-06 | |
| US4488608P | 2008-04-14 | 2008-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11244A true CR11244A (en) | 2010-05-20 |
Family
ID=40304796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11244A CR11244A (en) | 2007-07-30 | 2010-01-29 | DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP2184984A4 (en) |
| JP (3) | JP2010535232A (en) |
| KR (3) | KR20140098185A (en) |
| CN (2) | CN103479604B (en) |
| AP (1) | AP2817A (en) |
| AU (2) | AU2008282338B2 (en) |
| BR (1) | BRPI0815659A2 (en) |
| CA (1) | CA2693390C (en) |
| CO (1) | CO6470808A2 (en) |
| CR (1) | CR11244A (en) |
| DO (1) | DOP2010000045A (en) |
| EA (2) | EA020624B1 (en) |
| EC (1) | ECSP109910A (en) |
| HN (1) | HN2010000203A (en) |
| IL (1) | IL203296A (en) |
| MA (1) | MA31881B1 (en) |
| MX (1) | MX2010001244A (en) |
| NZ (1) | NZ582929A (en) |
| PH (1) | PH12015501914A1 (en) |
| SV (1) | SV2010003469A (en) |
| TN (1) | TN2010000049A1 (en) |
| WO (1) | WO2009018233A1 (en) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| US8808742B2 (en) * | 2008-04-14 | 2014-08-19 | Ardea Biosciences, Inc. | Compositions and methods for preparing and using same |
| KR101822319B1 (en) * | 2008-09-09 | 2018-01-25 | 에프. 호프만-라 로슈 아게 | Polymorphs of acyl sulfonamides |
| TWI506037B (en) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | Frizzled-binding agents and uses thereof |
| UY32486A (en) * | 2009-03-11 | 2010-10-29 | Ardea Biosciences Inc | TREATMENT OF CANCER CANCER |
| SG174272A1 (en) * | 2009-03-11 | 2011-10-28 | Ardea Biosciences Inc | Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers |
| CN102666512B (en) | 2009-10-13 | 2014-11-26 | 奥斯特姆医疗公司 | Novel MEK inhibitors, useful in the treatment of diseases |
| EP2491015A1 (en) * | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
| CN102020651B (en) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor |
| CN102649773A (en) * | 2011-02-23 | 2012-08-29 | 苏州波锐生物医药科技有限公司 | Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor |
| BR112013027448A2 (en) * | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | combination therapy with hsp90 |
| UA113850C2 (en) * | 2011-05-27 | 2017-03-27 | CHIRAL SYNTHESIS N- {3,4-DIFLUTOR-2 - $ (2-FLUORO-4-IODPHENYL) AMINO] -6-METHOXYPHENYL} -1- $ 2,3-DYHYDROXYPROPYL] CYCLOPROPANSPANE | |
| US20150132301A1 (en) * | 2011-12-09 | 2015-05-14 | Oncomed Pharmaceuticals, Inc. | Combination Therapy for Treatment of Cancer |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| KR20150013332A (en) * | 2012-05-31 | 2015-02-04 | 바이엘 파마 악티엔게젤샤프트 | Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients |
| WO2013184572A1 (en) | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| PL3702351T3 (en) * | 2012-10-19 | 2024-04-02 | Array Biopharma, Inc. | Formulation comprising a mek inhibitor |
| EP2916859B1 (en) | 2012-11-02 | 2017-06-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| JP2016510411A (en) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods and monitoring of treatment with WNT pathway inhibitors |
| EP2848246A1 (en) | 2013-09-13 | 2015-03-18 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| WO2015196072A2 (en) | 2014-06-19 | 2015-12-23 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN106535931A (en) * | 2014-08-25 | 2017-03-22 | 艾慕恩治疗公司 | Egg protein formulations and methods of manufacture thereof |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| AU2018283289B2 (en) | 2017-06-16 | 2021-03-25 | Beta Pharma, Inc. | Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021067772A1 (en) * | 2019-10-04 | 2021-04-08 | Sumitomo Dainippon Pharma Oncology, Inc. | Axl inhibitor formulations |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
| CN118834328B (en) * | 2024-07-02 | 2025-09-16 | 江苏海洋大学 | Preparation method and application of metalloprotease 9 epitope imprinting nano-particles |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162117A (en) * | 1991-11-22 | 1992-11-10 | Schering Corporation | Controlled release flutamide composition |
| JP2575590B2 (en) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation |
| JP3657002B2 (en) * | 1992-08-25 | 2005-06-08 | ジー．ディー．サール アンド カンパニー | Alpha- and beta-amino acid hydroxyethylaminosulfonamides useful as retroviral protease inhibitors |
| US7115632B1 (en) * | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| GEP20032999B (en) * | 1999-01-13 | 2003-06-25 | Warner Lambert Co | 1-Heterocycle Substituted Diarylamines |
| GB0003224D0 (en) * | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| CA2461227C (en) * | 2001-09-24 | 2012-05-15 | Jessie L.-S Au | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy |
| US20060089410A1 (en) * | 2002-07-17 | 2006-04-27 | Titan Pharmaceuticals, Inc. | Combination of chemotherapeutic drugs for increasing antitumor activity |
| JP2005535688A (en) * | 2002-07-30 | 2005-11-24 | ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Use of alkylphosphocholines in combination with antitumor drugs |
| BRPI0607537A2 (en) * | 2005-04-12 | 2009-09-15 | Elan Pharma Int Ltd | nanoparticulate quinazoline derivative formulations |
| CA2605381A1 (en) * | 2005-04-22 | 2006-11-02 | Kissei Pharmaceutical Co., Ltd. | Crystal polymorphism of 4'-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3',5'-dimethylbiphenylcarboxylic acid hydrochloride |
| WO2007014011A2 (en) * | 2005-07-21 | 2007-02-01 | Ardea Biosciences, Inc. | N-(arylamino)-sulfonamide inhibitors of mek |
| JP2007099763A (en) * | 2005-09-08 | 2007-04-19 | Toyama Chem Co Ltd | Novel crystals of piperacillin sodium monohydrate and process for producing the same |
| TW200800150A (en) * | 2005-12-21 | 2008-01-01 | Organon Nv | Compounds with medicinal effects due to interaction with the glucocorticoid receptor |
-
2008
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/en not_active Ceased
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/en active Pending
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/en not_active Ceased
- 2008-07-28 EA EA201000268A patent/EA020624B1/en not_active IP Right Cessation
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/en not_active Expired - Fee Related
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/en active IP Right Grant
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 EA EA201400552A patent/EA032294B1/en not_active IP Right Cessation
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/en not_active Application Discontinuation
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/en not_active Ceased
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en not_active Ceased
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 AP AP2010005134A patent/AP2817A/en active
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/en not_active Expired - Fee Related
-
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/en unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/en unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/en unknown
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/en unknown
- 2010-01-29 CO CO10009526A patent/CO6470808A2/en not_active Application Discontinuation
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/en unknown
- 2010-01-29 CR CR11244A patent/CR11244A/en not_active Application Discontinuation
- 2010-02-19 MA MA32636A patent/MA31881B1/en unknown
-
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/en not_active Expired - Fee Related
-
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
-
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6470808A2 (en) | DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME | |
| ECSP088749A (en) | TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE | |
| UY31481A1 (en) | NEW PIRIMIDINE DERIVATIVES, PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| UY29795A1 (en) | ADENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS | |
| UY31254A1 (en) | SUBSTITUTED DERIVATIVES OF N4- (5-METHYL-1H-PIRAZOL-3-IL) - 1,3,5-TRIAZINA-2,4-DIAMINE, THEIR ENANTIOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS, PREPARATION PROCESSES AND APPLICATIONS | |
| UY31524A1 (en) | NEW COMPOUNDS 010 | |
| DOP2006000193A (en) | ISOINDOL-IMIDA COMPOUNDS AND COMPOSITIONS INCLUDING THEM AND METHODS FOR USE | |
| CR20110028A (en) | PIRIMIDINE DERIVATIVES AS CINASE INHIBITORS | |
| ECSP077268A (en) | RAPAMYCIN POLYMORPH II AND THE USES OF THE SAME | |
| UY30976A1 (en) | NEW DERIVATIVES OF QUINOLINA, PHARMACCUTIC COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCESSES AND APPLICATIONS. | |
| UY32611A (en) | 1-CYANOETHYLETHYCLIC CARBOXAMIDE SUBSTITUTED COMPOUNDS 750 | |
| CR11861A (en) | ORGANIC COMPOUNDS | |
| CL2015002635A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| MX388468B (en) | MULTICYCLIC COMPOUNDS AND METHODS OF USING THEM. | |
| CL2007002733A1 (en) | COMPOUNDS DERIVED FROM 2-ARIL-6-PHENYL-IMIDAZO [1,2-A] PIRIDINES; PROCEDURE FOR OBTAINING COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES, OSTEOPOROSIS AND CANCER. | |
| EA201390908A1 (en) | DERIVATIVES OF BICYCLO [3.2.1] OCTYLAMIDE AND THEIR APPLICATION | |
| UY30748A1 (en) | NEW COMPOUNDS | |
| UY28745A1 (en) | NEW COMPOUNDS | |
| ECSP13012600A (en) | CO-crystals and salts of CCR3 inhibitors | |
| CR9663A (en) | 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM | |
| GT200600013A (en) | ORGANIC COMPOUNDS | |
| UY29767A1 (en) | BENZOTIAZOLONAS DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS | |
| UY29414A1 (en) | PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | |
| CR9257A (en) | CCI-779 POLYMORPH AND USE OF IT | |
| CO6321280A2 (en) | NEW ESPIRO PIPERIDINAS CLASS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |